NCT06780046 Study That Will Evaluate the Brazilian Population With COPD.
| NCT ID | NCT06780046 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AstraZeneca |
| Condition | COPD (Chronic Obstructive Pulmonary Disease) |
| Study Type | OBSERVATIONAL |
| Enrollment | 693 participants |
| Start Date | 2025-01-31 |
| Primary Completion | 2027-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 693 participants in total. It began in 2025-01-31 with a primary completion date of 2027-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Observational, prospective, multicenter cohort study with consecutive inclusion of COPD patients. Eligible patients will be those with severe and very severe COPD according to the GOLD 2024 (Global Initiative for Chronic Obstructive Lung Disease) guidelines being followed at participating hospitals. The severity of COPD is related to the exacerbation rate, which in turn is related to the progression of the disease and the occurrence of complications and death. There is no national data on this subgroup.
Eligibility Criteria
Inclusion Criteria: * Patients of both sexes, aged 18 years or older, with confirmed COPD according to GOLD 2024: previous or current exposure and spirometry (FEV1/FVC =2 or CAT \>=10); or * GOLD E (\>=2 moderate or 1 severe exacerbation - hospitalization); or * GOLD 3 and 4 (FEV1 \<50%). Exclusion Criteria: * Advanced fibrosing interstitial lung disease (extent \>=50%); and/or * High-risk pulmonary hypertension (on triple therapy); and/or * Active cancer - on systemic therapy
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06780046 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying COPD (Chronic Obstructive Pulmonary Disease). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06780046 currently recruiting?
Yes, NCT06780046 is actively recruiting participants. Contact the research team at information.center@astrazeneca.com for enrollment information.
Where is the NCT06780046 trial being conducted?
This trial is being conducted at Aparecida de Goiânia, Brazil, Bahia, Brazil, Belém, Brazil, Brasília, Brazil and 6 additional locations.
Who is sponsoring the NCT06780046 clinical trial?
NCT06780046 is sponsored by AstraZeneca. The trial plans to enroll 693 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.